ra·lox·i·fene

(rə-lŏk′sĭ-fēn′)

A selective estrogen receptor modulator, C₂₈H₂₇NO₄S, used in the form of its hydrochloride primarily to treat and prevent osteoporosis in postmenopausal women.

[ral-, of unknown origin + (eth)oxy + alteration and blend of phen(yl) and -ene.]

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

ra•lox•i•fene

(rəˈlɒk səˌfin)
n.

a drug, C₂₈H₂₇NO₄S, prescribed primarily to prevent postmenopausal osteoporosis.

Translations

raloxifene

n raloxifeno

Mentioned in

References in periodicals archive

The researchers found that tamoxifen, raloxifene, and the aromatase inhibitors exemestane and anastrozole correlated with a reduced incidence of invasive breast cancer in placebo-controlled trials (risk ratios, 0.69, 0.44, and 0.45, respectively).

USPSTF Advises Meds to Reduce Risk for Primary Breast Cancer; Offer risk-reducing meds to women at higher risk for breast cancer, low risk for adverse medication effects

(5) Thus, it is evident that, in the endometrium, ospemifene is much more like the SERM raloxifene than it is like estrogen.

New important data on ospemifene

Raloxifene is a SERM that acts as an estrogen agonist in some tissues, but an antagonist in uterine and breast tissue, which may minimize potential deleterious adverse effects (Table 2, (21-24) page 49).

Decompensation in a 51-year-old woman with schizophrenia

We report the case of a woman who suffered spontaneous clinical vertebral fractures at denosumab discontinuation despite a preventive treatment with raloxifene.

Raloxifene Has No Efficacy in Reducing the High Bone Turnover and the Risk of Spontaneous Vertebral Fractures after Denosumab Discontinuation

The members of the benzothiophene class of SERMs include raloxifene, arzoxifene, bazedoxifene, and lasofoxifene, which are used primarily for the treatment of osteoporosis; however, raloxifene has also been approved for the treatment of breast cancer in high-risk postmenopausal women [23-25].

Translational Significance of Selective Estrogen Receptor Modulators in Psychiatric Disorders

The American College of Physicians' updated clinical practice guideline for treating osteoporosis strongly advocates bisphosphonates and strongly advises against estrogens or raloxifene. It was presented online May 8 in Annals of Internal Medicine.

ACP's updated osteoporosis guideline advocates use of bisphosphonates, nixes estrogen prescription

Estrogens or raloxifene are not advised for established osteoporosis, because good evidence shows they do not reduce fracture risk, according to the guideline.

ACP osteoporosis guideline backs bisphosphonates

The cost watchdog has advised that doctors prescribe either tamoxifen, raloxifene or anastrozole to hundreds of thousands of 'healthy' women who may not have a personal history of the disease, but are at a heightened risk of developing it.

NICE recommends three preventative breast cancer drugs

The osteoporosis drug raloxifene (Evista) failed to improve memory and thinking skills in women with Alzheimer's disease (AD), according to a study published online Nov.

Bone drug ineffective for improving cognitive function

Raloxifene (raloxifene hydrochloride), a non-hormone drug against bone resorption, belongs to the second generation of selective estrogen receptor modulator (SERMs).

Report Published: "China Raloxifene Market, 2010-2019"